Edition:
United Kingdom

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

575.20INR
16 Feb 2018
Change (% chg)

Rs-2.05 (-0.36%)
Prev Close
Rs577.25
Open
Rs575.70
Day's High
Rs577.00
Day's Low
Rs564.15
Volume
650,191
Avg. Vol
514,717
52-wk High
Rs728.45
52-wk Low
Rs433.15

Select another date:

Wed, Feb 14 2018

UPDATE 1-India's Sun Pharma quarterly profit plunges on weak U.S. sales

* Profit hit by one-time deferred tax adjustment (Adds details)

BRIEF-Sun Pharma Industries Says Qtrly US Finished Dosage Sales Down 35 Pct

* SAYS US FINISHED DOSAGE SALES DURING QUARTER AT US$ 328 MILLION, DOWN 35 PERCENT OVER Q3 LAST YEAR Source text for Eikon: Further company coverage:

India's Sun Pharma Q3 profit slides 75 pct, misses estimates

Feb 14 India's largest drugmaker Sun Pharmaceutical Industries Ltd reported on Wednesday a 75 percent drop in net profit in the quarter ending Dec. 31, well below analysts' estimates.

BRIEF-India's Sun Pharmaceutical Industries Dec-Qtr Consol Profit Down 75 Pct

* DEC QUARTER CONSOL NET PROFIT AFTER TAX 3.65 BILLION RUPEES VERSUS PROFIT OF 14.72 BILLION RUPEES LAST YEAR

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

BRIEF-Sun Pharmaceutical Industries Announces U.S FDA Acceptance Of NDA For OTX-101

* ANNOUNCES U.S FDA ACCEPTANCE OF NDA FOR OTX-101 Source text - http://bit.ly/2BDUZEZ Further company coverage:

BRIEF-Sun Pharmaceutical Industries Reports 12.3 Percent Stake In Scpharmaceuticals As Of November 21

* SUN PHARMACEUTICAL INDUSTRIES LIMITED REPORTS 12.3 PERCENT STAKE IN SCPHARMACEUTICALS INC AS OF NOVEMBER 21 - SEC FILING‍​

BRIEF-Sun Pharma Industries MD says no new updates on Halol; awaiting FDA re-inspection of plants‍​

Nov 14 Sun Pharmaceutical Industries managing director Dilip Shanghvi says:

UPDATE 1-India's Sun Pharma posts profit dive on U.S. pricing pressure

* Q2 profit down 59 pct * Indian sales rise 11 pct * U.S. sales down 44 pct (Adds detail, executive comment) Nov 14 India's largest drugmaker Sun Pharmaceutical Industries reported a 59 percent plunge in second-quarter profit on Tuesday, hurt by generics pricing pressure in the United States. Along with other Indian drugmakers, Sun Pharma has had sales dented by rising competition in the generics market and greater pricing scrutiny in the United States,

BRIEF-Sun Pharmaceutical Industries approves scheme of arrangement between co & Sun Pharma Global FZE

* Says approves scheme of arrangement among Sun Pharma Global FZE & co‍​

Select another date: